Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BeNeLuxA Medicine Access Collaboration Plans Joint Horizon Scanning

Executive Summary

Belgium, the Netherlands, Luxemburg and Austria are continuing their collaboration on improving access to medicines and are finalizing a proposal on a joint horizon scanning initiative.

You may also be interested in...

After Canada, Sweden Shows Interest In BeNeLuxA Joint Horizon Scanning

Dutch minister for medical care Bruno Bruins is hopeful that 10 countries will have joined the International Horizon Scanning Initiative when it kicks off in October.

EFPIA Works To Get Industry View Included In Horizon Scanning Initiatives

The European Federation of Pharmaceutical Industries and Associations is preparing its principles on horizon scanning.

Portugal Uses Horizon Scanning To Speed Up Market Entry For Innovative Drugs

Portugal’s medicines regulator, Infarmed, wants to prioritize new medicines and speed up access to innovation with a new horizon scanning initiative.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts